doiSerbia

Detection of laboratory biomarkes in haematological and pulmonology patients at high risk for aspergillosis

Ratkov Eleonora (Referentna laboratorija za uzročnike mikoza, Institut za mikrobiologiju i imunologiju, Medicinski fakultet, Beograd)
Vidović Ana (Klinika za hematologiju, Klinički centar Srbije, Beograd + Medicinski fakultet, Beograd)
Minić Predrag (Medicinski fakultet, Beograd + Institut za zdravstvenu zaštitu majke i deteta Srbije „Dr Vukan Čupić”, Beograd)
Janić Dragana (Medicinski fakultet, Beograd + Odeljenje za hematoonkologiju, Univerzitetska dečja klinika, Beograd)
Šipetić-Grujičić Sandra (Institut za epidemiologiju, Medicinski fakultet, Beograd)
Džamić Aleksandar (Referentna laboratorija za uzročnike mikoza, Institut za mikrobiologiju i imunologiju, Medicinski fakultet, Beograd)
Arsić-Arsenijević Valentina (Referentna laboratorija za uzročnike mikoza, Institut za mikrobiologiju i imunologiju, Medicinski fakultet, Beograd)

Introduction. During the past decades a dramatic increase in the incidence of invasive fungal diseases, especially invasive aspergillosis has been observed. Undiagnosed and diagnosed late invasive aspergillosis is followed by lethality of up to 90%. Detection of early laboratory biomarkers (galactomannan and anti-Aspergillus antibodies) contributes to early diagnosis and is used for screening, as well as for monitoring therapy of aspergillosis. Objective. The aim was to evaluate usefulness of “non-culture” methods (galactomannan and anti-Aspergillus antibodies IgA, IgM and IgG) for early diagnosis of aspergillosis in high-risk patients. Methods. Prospective two-year study involved 262 high-risk patients for aspergillosis. In pulmonology and haematology patients (adults and children) blood samples were tested on galactomannan and anti-Aspergillus antibodies. Results. Early laboratory biomarkers were statistically significantly higher in pulmonology patients (p=0.00033). However, in haematological patients galactomannan was a more frequently positive finding, while in pulmonology patients it was the finding of anti-Aspergillus antibodies. It is interesting that, despite the possible immunosuppression, in about 1/3 of haematological patients anti-Aspergillus antibodies were confirmed. Conclusion. Early diagnosis and treatment of aspergillosis represent both clinical and laboratory problem. Nowadays, the application of new “non-culture” methods is of particular importance for the outcome of aspergillosis. Clinical features, laboratory findings of biomarkers and their correct interpretation significantly increase the possibility of timely implementation of appropriate therapy. In this regard, the new organization of reference laboratory for medical mycology has significantly improved the outcome of aspergillosis in high-risk patients in our country. However, further investigations, implementation of European standards and introduction of new diagnostic methods are necessary in this field.

Keywords: aspergillosis, early laboratory diagnosis, galactomannan, anti-Aspergillus antibodies, high-risk patients